130 related articles for article (PubMed ID: 8978703)
1. Two intracellular signaling pathways for the dopamine D3 receptor: opposite and synergistic interactions with cyclic AMP.
Griffon N; Pilon C; Sautel F; Schwartz JC; Sokoloff P
J Neurochem; 1997 Jan; 68(1):1-9. PubMed ID: 8978703
[TBL] [Abstract][Full Text] [Related]
2. Functional coupling of the human dopamine D3 receptor in a transfected NG 108-15 neuroblastoma-glioma hybrid cell line.
Pilon C; Lévesque D; Dimitriadou V; Griffon N; Martres MP; Schwartz JC; Sokoloff P
Eur J Pharmacol; 1994 Jul; 268(2):129-39. PubMed ID: 7957635
[TBL] [Abstract][Full Text] [Related]
3. Heterologous sensitization of adenylate cyclase is protein kinase A-dependent in Cath.a differentiated (CAD)-D2L cells.
Johnston CA; Beazely MA; Vancura AF; Wang JK; Watts VJ
J Neurochem; 2002 Sep; 82(5):1087-96. PubMed ID: 12358756
[TBL] [Abstract][Full Text] [Related]
4. Selective inhibition of adenylyl cyclase type V by the dopamine D3 receptor.
Robinson SW; Caron MG
Mol Pharmacol; 1997 Sep; 52(3):508-14. PubMed ID: 9281614
[TBL] [Abstract][Full Text] [Related]
5. Dopamine D3 receptor-preferring agonists increase dendrite arborization of mesencephalic dopaminergic neurons via extracellular signal-regulated kinase phosphorylation.
Collo G; Zanetti S; Missale C; Spano P
Eur J Neurosci; 2008 Oct; 28(7):1231-40. PubMed ID: 18973551
[TBL] [Abstract][Full Text] [Related]
6. Efficient functional coupling of the human D3 dopamine receptor to G(o) subtype of G proteins in SH-SY5Y cells.
Zaworski PG; Alberts GL; Pregenzer JF; Im WB; Slightom JL; Gill GS
Br J Pharmacol; 1999 Nov; 128(6):1181-8. PubMed ID: 10578130
[TBL] [Abstract][Full Text] [Related]
7. Regulation of responsiveness at D2 dopamine receptors by receptor desensitization and adenylyl cyclase sensitization.
Bates MD; Senogles SE; Bunzow JR; Liggett SB; Civelli O; Caron MG
Mol Pharmacol; 1991 Jan; 39(1):55-63. PubMed ID: 1846220
[TBL] [Abstract][Full Text] [Related]
8. D2 dopamine receptor-mediated inhibition of a hyperpolarization-activated current in rod photoreceptors.
Akopian A; Witkovsky P
J Neurophysiol; 1996 Sep; 76(3):1828-35. PubMed ID: 8890295
[TBL] [Abstract][Full Text] [Related]
9. Activation of type II adenylate cyclase by D2 and D4 but not D3 dopamine receptors.
Watts VJ; Neve KA
Mol Pharmacol; 1997 Aug; 52(2):181-6. PubMed ID: 9271339
[TBL] [Abstract][Full Text] [Related]
10. Phosphorylation- and voltage-dependent inhibition of neuronal calcium currents by activation of human D2(short) dopamine receptors.
Brown NA; Seabrook GR
Br J Pharmacol; 1995 Jun; 115(3):459-66. PubMed ID: 7582457
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of dopamine synthesis by dopamine D2 and D3 but not D4 receptors.
O'Hara CM; Uhland-Smith A; O'Malley KL; Todd RD
J Pharmacol Exp Ther; 1996 Apr; 277(1):186-92. PubMed ID: 8613917
[TBL] [Abstract][Full Text] [Related]
12. Sensitization of endogenous and recombinant adenylate cyclase by activation of D2 dopamine receptors.
Watts VJ; Neve KA
Mol Pharmacol; 1996 Oct; 50(4):966-76. PubMed ID: 8863843
[TBL] [Abstract][Full Text] [Related]
13. Antipsychotics with inverse agonist activity at the dopamine D3 receptor.
Griffon N; Pilon C; Sautel F; Schwartz JC; Sokoloff P
J Neural Transm (Vienna); 1996; 103(10):1163-75. PubMed ID: 9013403
[TBL] [Abstract][Full Text] [Related]
14. The human D2 dopamine receptor synergizes with the A2A adenosine receptor to stimulate adenylyl cyclase in PC12 cells.
Kudlacek O; Just H; Korkhov VM; Vartian N; Klinger M; Pankevych H; Yang Q; Nanoff C; Freissmuth M; Boehm S
Neuropsychopharmacology; 2003 Jul; 28(7):1317-27. PubMed ID: 12784121
[TBL] [Abstract][Full Text] [Related]
15. Modulation of cyclic AMP levels in a clonal neural cell line by inhibitors of tyrosine phosphorylation.
Stringfield TM; Morimoto BH
Biochem Pharmacol; 1997 May; 53(9):1271-8. PubMed ID: 9214688
[TBL] [Abstract][Full Text] [Related]
16. In vitro characterization of SLV308 (7-[4-methyl-1-piperazinyl]-2(3H)-benzoxazolone, monohydrochloride): a novel partial dopamine D2 and D3 receptor agonist and serotonin 5-HT1A receptor agonist.
Glennon JC; Van Scharrenburg G; Ronken E; Hesselink MB; Reinders JH; Van Der Neut M; Long SK; Feenstra RW; McCreary AC
Synapse; 2006 Dec; 60(8):599-608. PubMed ID: 17001660
[TBL] [Abstract][Full Text] [Related]
17. Dopamine D3 receptors in rat juxtaglomerular cells.
Sanada H; Yao L; Jose PA; Carey RM; Felder RA
Clin Exp Hypertens; 1997; 19(1-2):93-105. PubMed ID: 9028638
[TBL] [Abstract][Full Text] [Related]
18. Determination of D1 and D2 dopamine receptor expression by Ntera-2 cells.
Sakolsky DJ; Ashby B
Brain Res Mol Brain Res; 2000 Dec; 84(1-2):158-61. PubMed ID: 11113544
[TBL] [Abstract][Full Text] [Related]
19. Dopaminergic inhibition of catecholamine secretion from chromaffin cells: evidence that inhibition is mediated by D4 and D5 dopamine receptors.
Dahmer MK; Senogles SE
J Neurochem; 1996 Jan; 66(1):222-32. PubMed ID: 8522958
[TBL] [Abstract][Full Text] [Related]
20. The agonist activities of the putative antipsychotic agents, L-745,870 and U-101958 in HEK293 cells expressing the human dopamine D4.4 receptor.
Gazi L; Bobirnac I; Danzeisen M; Schüpbach E; Bruinvels AT; Geisse S; Sommer B; Hoyer D; Tricklebank M; Schoeffter P
Br J Pharmacol; 1998 Jul; 124(5):889-96. PubMed ID: 9692773
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
